Evidence map›Paper›PMID 32583309›Full record

ArticlePurinergic signalling2020

P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas.

Liyen Katrina Kan, Sinali Seneviratne, Kate J Drummond, David A Williams, Terence J O'Brien, Mastura Monif

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Liyen Katrina KanDepartment of Neuroscience, Central Clinical School, Monash University, Level 6, 99 Commercial Rd, Melbourne, VIC, 3004, Australia.
Sinali SeneviratneCurtin University, Perth, WA, Australia.
Kate J DrummondDepartment of Neurosurgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
David A WilliamsDepartment of Physiology, The University of Melbourne, Melbourne, VIC, Australia.
Terence J O'BrienDepartment of Neuroscience, Central Clinical School, Monash University, Level 6, 99 Commercial Rd, Melbourne, VIC, 3004, Australia.
Mastura MonifDepartment of Neuroscience, Central Clinical School, Monash University, Level 6, 99 Commercial Rd, Melbourne, VIC, 3004, Australia. mastura.monif@monash.edu.ORCID 0000-0001-6404-9768
The Royal Melbourne Hospital · AUThe University of Melbourne · AUCurtin University · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas, the most common primary brain cancer, are highly infiltrative and extremely difficult to treat. Despite advancements, current treatment is limited, with patients surviving for a median of 14-15 months post-diagnosis. Previous research has demonstrated the upregulation of a purinergic receptor, P2X7R, in human gliomas. P2X7R is expressed on both glioma cells and microglia within the glioma microenvironment. It is hypothesized that P2X7R contributes to tumour growth and proliferation via immune-mediated mechanisms involving tumour cells and surrounding microglia. We sought to elucidate the role of P2X7R in a human glioblastoma cell line (U251) and on surgically resected human glioma samples. We treated U251 and human glioma cultures for 72 h with P2X7R antagonists, Brilliant Blue G (BBG), oxidized ATP (oATP) and AZ10606120. Cell counting via fluorescence confocal microscopy was conducted to assess tumour proliferation. We observed no significant reductions in tumour cell numbers following P2X7R antagonism with BBG (20 μM) and oATP (250 μM) in both U251 cells and human glioma samples. Interestingly, there was a significant reduction in tumour cell number in both U251 cells (p = 0.0156) and human glioma samples (p = 0.0476) treated with varying concentrations of AZ10606120. When compared with the conventional chemotherapeutic agent, temozolomide, AZ10606120 was also found to more effectively inhibit tumour proliferation in U251 cells (p < 0.0001). Our pilot results demonstrate a potential trophic role of P2X7R where its inhibition by AZ10606120, a potent antagonist, hinders glioma growth directly or through the inactivation of microglia. This sheds new light on P2X7R as a therapeutic target for human gliomas.

Indexed as

AdamantaneAminoquinolinesBrain NeoplasmsCell Line, TumorCell ProliferationGliomaHumansMicrogliaMicroscopy, ConfocalPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7Rosaniline DyesSignal TransductionTumor MicroenvironmentAdamantaneAminoquinolinesAZ10606120coomassie Brilliant BluePurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7Rosaniline DyesCancerGlioblastomaGliomaP2X7RP2X7 receptor

Identifiers

PMID32583309
PMCPMC7524927
OpenAlexW3037029459

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.